CD274 and metastatic neoplasm: Median progression free survival (mPFS) to anti-PD-1/PD-L1 was 14.5 months (95% CI, 2.1-NR), and median overall survival (mOS) of metastatic disease was 63.9 months (95% CI, 45.6-NR) (Supplementary Figures S1 and S2).